AR117626A1 - COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA - Google Patents

COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA

Info

Publication number
AR117626A1
AR117626A1 ARP190102127A ARP190102127A AR117626A1 AR 117626 A1 AR117626 A1 AR 117626A1 AR P190102127 A ARP190102127 A AR P190102127A AR P190102127 A ARP190102127 A AR P190102127A AR 117626 A1 AR117626 A1 AR 117626A1
Authority
AR
Argentina
Prior art keywords
highly concentrated
proteinase inhibitor
procedure
obtaining
same
Prior art date
Application number
ARP190102127A
Other languages
English (en)
Inventor
Kelly Glancy
Michelle Speter
Kevin Wee
Thomas P Zimmerman
Eric Allgaier
Anthony Klos
Charles Miller
James Rebbeor
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of AR117626A1 publication Critical patent/AR117626A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las composiciones incluyen inhibidor de la a-1 proteinasa (A1PI) altamente concentrado en una concentración superior o igual a 100 mg/ml. Las composiciones farmacéuticas se pueden preparar a partir de estas composiciones. Las composiciones farmacéuticas pueden ser adecuadas para la administración subcutánea. Las soluciones de A1PI altamente concentrado se pueden obtener mediante filtración tangencial sin recirculación “single pass” (SPTFF).
ARP190102127A 2018-08-02 2019-07-29 COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA AR117626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862713673P 2018-08-02 2018-08-02

Publications (1)

Publication Number Publication Date
AR117626A1 true AR117626A1 (es) 2021-08-18

Family

ID=67439017

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102127A AR117626A1 (es) 2018-08-02 2019-07-29 COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA

Country Status (15)

Country Link
US (3) US11253578B2 (es)
EP (1) EP3632412A1 (es)
JP (2) JP7458717B2 (es)
KR (1) KR20200015409A (es)
CN (1) CN110787297B (es)
AR (1) AR117626A1 (es)
AU (1) AU2019204927A1 (es)
BR (1) BR102019014292A2 (es)
CA (1) CA3049584A1 (es)
CL (1) CL2019002131A1 (es)
IL (1) IL267923B2 (es)
MX (1) MX2019008968A (es)
SG (1) SG10201906599VA (es)
TW (1) TWI833778B (es)
UY (1) UY38315A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
IL295661A (en) * 2020-02-25 2022-10-01 Grifols Worldwide Operations Ltd A method for obtaining an inhibitor of proteinase alpha-1

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
JP4072057B2 (ja) 2000-12-27 2008-04-02 アレス トレーディング ソシエテ アノニム ペプチド及び／またはタンパク質取り込み用の両親媒性脂質ナノ粒子
JP2006523609A (ja) 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
SI1664123T2 (sl) * 2003-09-22 2012-03-30 Kamada Ltd Priprava inhibitorja alfa proteinaze v velikem merilu in njegova uporaba
JP2007534633A (ja) 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
PL1684719T3 (pl) * 2003-11-14 2012-11-30 Baxalta Inc Kompozycje alfa 1-antytrypsyny i sposoby leczenia z zastosowaniem takich kompozycji
RU2268736C1 (ru) 2004-06-17 2006-01-27 Общество с ограниченной ответственностью "БиоГениус" Способ получения альфа-1-антитрипсина и продукт для использования в медицине
US7384549B2 (en) 2005-12-29 2008-06-10 Spf Innovations, Llc Method and apparatus for the filtration of biological solutions
PT2214699T (pt) 2007-11-02 2017-01-10 Grifols Therapeutics Inc Método, composição e artigo de fabrico para proporcionar alfa-1 antitripsina
CA2730018A1 (en) 2008-07-18 2010-01-21 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
JP2013510158A (ja) 2009-11-03 2013-03-21 グリフオルス・セラピユーテイクス・インコーポレーテツド α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
EP4043025A1 (en) * 2011-06-08 2022-08-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CN103788209B (zh) * 2012-10-29 2016-02-24 广东双林生物制药有限公司 一种α1-蛋白酶抑制剂的制备方法
US10550148B2 (en) * 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
US20170312282A1 (en) * 2016-04-28 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it

Also Published As

Publication number Publication date
US11253578B2 (en) 2022-02-22
CL2019002131A1 (es) 2020-03-20
SG10201906599VA (en) 2020-03-30
JP2020019765A (ja) 2020-02-06
TW202019945A (zh) 2020-06-01
JP7458717B2 (ja) 2024-04-01
KR20200015409A (ko) 2020-02-12
JP2024040213A (ja) 2024-03-25
US20220000992A1 (en) 2022-01-06
EP3632412A1 (en) 2020-04-08
US20200038494A1 (en) 2020-02-06
CN110787297A (zh) 2020-02-14
IL267923A (en) 2020-02-27
UY38315A (es) 2020-02-28
AU2019204927A1 (en) 2020-02-20
US20230277636A1 (en) 2023-09-07
CA3049584A1 (en) 2020-02-02
IL267923B2 (en) 2023-06-01
CN110787297B (zh) 2023-08-18
BR102019014292A2 (pt) 2020-02-18
MX2019008968A (es) 2020-02-03
TWI833778B (zh) 2024-03-01
US11701412B2 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
CY1118017T1 (el) Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CU20100203A7 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de la hepatitis c
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
AR050717A1 (es) Composiciones farmaceuticas
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
AR117626A1 (es) COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA
MX2020012478A (es) Metodos y composiciones para el tratamiento de la hipertension pulmonar.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
DOP2021000028A (es) Formulaciones de dendrímeros
CR9316A (es) Derivados de amida como ligando de canales ionicos y composiciones farmaceuticas y metodos para usar los mismos
EA202192422A1 (ru) Человеческий сывороточный альбумин в составах
WO2020053658A3 (en) Non-aqueous chemotherapeutic solutions for oral dosage
BR0312452A (pt) Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama)
AR108792A1 (es) Composiciones que comprenden timolol
MX2020013574A (es) Composicion farmaceutica para la administracion oral que comprende un inhibidor de la bomba de protones con absorcion mejorada.